What is the appropriate oral vancomycin dosing regimen for Clostridioides difficile infection?

Vancomycin Dosing for C. difficile Infection

For initial C. difficile infection, use oral vancomycin 125 mg four times daily for 10 days, though fidaxomicin is now preferred as first-line therapy when available. 1

Dosing by Clinical Scenario

Initial Episode (Non-severe or Severe)

• Standard dose: 125 mg orally four times daily for 10 days 1, 2
• This dose applies to both non-severe (WBC ≤15,000 cells/μL and creatinine <1.5 mg/dL) and severe disease (WBC ≥15,000 cells/μL or creatinine >1.5 mg/dL) 3
• Important caveat: While fidaxomicin 200 mg twice daily is now the preferred first-line agent per 2021 IDSA/SHEA guidelines, vancomycin remains an acceptable alternative 1

Fulminant CDI

• High-dose vancomycin: 500 mg orally four times daily 1
• Administer by mouth or nasogastric tube
• If ileus present: Add rectal vancomycin 500 mg in 100 mL normal saline every 6 hours as retention enema 3
• Always add: IV metronidazole 500 mg every 8 hours, particularly when ileus is present 1, 3
• Fulminant disease is defined by hypotension/shock, ileus, or megacolon 1

First Recurrence

Three acceptable options 1:

1. Tapered and pulsed vancomycin regimen (preferred):

   • 125 mg four times daily for 10-14 days
   • Then 125 mg twice daily for 7 days
   • Then 125 mg once daily for 7 days
   • Then 125 mg every 2-3 days for 2-8 weeks 1

2. Standard course: 125 mg four times daily for 10 days (if metronidazole was used for initial episode) 1

3. Fidaxomicin: 200 mg twice daily for 10 days (preferred over standard vancomycin) 1

Second or Subsequent Recurrence

• Tapered and pulsed vancomycin regimen (as above) 1
• Alternative: 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days 1
• Consider fecal microbiota transplantation after at least 2 recurrences (3 total CDI episodes) 1

Critical Dosing Considerations

Higher Doses Are Not More Effective

Research evidence shows no benefit to doses >500 mg daily for non-fulminant disease. A 2021 study found no significant differences in recurrence (OR 1.52,95% CI 0.82-2.84), clinical failure, or mortality between standard 125 mg QID and high-dose ≥250 mg QID vancomycin 4. Similarly, a 2013 study showed no difference in cure rates (60% vs 64%, P=0.76) or time to cure between high-dose and low-dose vancomycin in severe CDI 5.

Route of Administration

• Oral administration only for CDI treatment 2
• IV vancomycin is NOT effective for CDI and should never be used 2
• Rectal administration is reserved only for fulminant disease with ileus 1

Duration

• Standard duration: 10 days for initial episodes 1, 2
• Some patients may require extension to 14 days if delayed response occurs 3
• Tapered/pulsed regimens extend up to 8 weeks total 1

Common Pitfalls to Avoid

1. Do not use IV vancomycin - it does not achieve adequate intestinal concentrations 2
2. Do not use 125 mg doses for fulminant disease - requires 500 mg QID 1
3. Do not use metronidazole as first-line - only acceptable when vancomycin/fidaxomicin unavailable for non-severe disease 1
4. Do not perform test of cure - only retest if symptoms persist or worsen 6
5. Do not use bile acid binders (cholestyramine) concurrently with vancomycin - they bind and inactivate the drug 6

Special Populations

Elderly Patients (>65 years)

• Monitor renal function during and after treatment - increased risk of nephrotoxicity 2
• Systemic absorption can occur, particularly with inflammatory bowel disease 2
• Consider serum vancomycin monitoring in patients with renal insufficiency receiving oral therapy 2

Pediatric Patients (<18 years)

• Dose: 40 mg/kg/day divided into 3-4 doses for 7-10 days 2
• Maximum daily dose: 2 grams 2